31 / 48
VOLUME 12 NUMBER 1 • JULY 2015
29
SA JOURNAL OF DIABETES & VASCULAR DISEASE
RESEARCH ARTICLE
18. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M,
et al.
Effectiveness
of statin therapy in adults with coronary heart disease.
Arch Int Med
2004;
164
(13): 1427–1436. PubMed PMID: 15249352. Epub 2004/07/14. eng.
19. Cholesterol treatment trialists, Baigent C, Blackwell L, Emberson J, Holland LE,
Reith C,
et al
. Efficacy and safety of more intensive lowering of LDL cholesterol: a
meta-analysis of data from 170,000 participants in 26 randomised trials.
Lancet
2010;
376
(9753): 1670–1681. PubMed PMID: 21067804. Pubmed Central
PMCID: 2988224.
20. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits
and diabetes risks of statin therapy in primary prevention: an analysis from the
JUPITER trial.
Lancet
2012;
380
(9841): 565–571. PubMed PMID: 22883507.
Epub 2012/08/14. eng.
21. Klug E. South African dyslipidaemia guideline consensus statement.
South Afr
Med J
2012;
102
(3 Pt 2): 178–187. PubMed PMID: 22380916. Epub 2012/03/03.
eng.
22. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, VerschurenWM,
et al
. European
Guidelines on cardiovascular disease prevention in clinical practice (version 2012):
The Fifth Joint Task Force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted
by representatives of nine societies and by invited experts).
Atherosclerosis
2012;
223
(1): 1–68. PubMed PMID: 22698795. Epub 2012/06/16. eng.
23. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB,
et al
. Implications of recent clinical trials for the National Cholesterol Education
Program Adult Treatment Panel III guidelines.
Circulation
2004;
110
(2): 227–239.
PubMed PMID: 15249516. Epub 2004/07/14. eng.
24. Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK,
et
al
. Persistent lipid abnormalities in statin-treated patients and predictors of
LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Eur J Prevent Cardiol
2012;
19
(2): 221–30. PubMed PMID: 21450578. Epub
2011/04/01. eng.
25. Leiter LA, Lundman P, da Silva PM, Drexel H, Junger C, Gitt AK. Persistent lipid
abnormalities in statin-treated patients with diabetes mellitus in Europe and
Canada: results of the Dyslipidaemia International Study.
Diabetic Med
2011;
28
(11): 1343–1351. PubMed PMID: 21679231. Epub 2011/06/18. eng.
26. Raal F, Schamroth C, Blom D, Marx J, Rajput M, Haus M,
et al
. CEPHEUS SA: a
South African survey on the undertreatment of hypercholesterolaemia.
Cardiovasc
J Afr
2011;
22
(5): 234–240. PubMed PMID: 21922121.
27. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Am J
Cardiol
1997;
80
(1): 106–107. PubMed PMID: 9205036. Epub 1997/07/01. eng.
28. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O,
et al
.
ESC/EAS Guidelines for the management of dyslipidaemias, the Task Force for the
management of dyslipidaemias of the European Society of Cardiology (ESC) and
the European Atherosclerosis Society (EAS).
Atherosclerosis
2011;
217
(1): 3–46.
PubMed PMID: 21882396. Epub 2011/09/02. eng.
29. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA,
et al
.
Diagnosis and management of the metabolic syndrome: an American Heart
Association/National Heart, Lung, and Blood Institute scientific statement: executive
summary.
Crit Pathways Cardiol
2005;
4
(4): 198–203. PubMed PMID: 18340209.
30. Al Sifri SN, Almahmeed W, Azar S, Okkeh O, Bramlage P, Jünger C,
et al
. Results
of the Dyslipidemia International Study (DYSIS)-Middle East: a clinical perspective
on the prevalence and characteristics of lipid abnormalities in the setting of
chronic statin treatment. In press 2013.
31. Hempler NF, Diderichsen F, Larsen FB, Ladelund S, Jorgensen T. Do immigrants
from Turkey, Pakistan and Yugoslavia receive adequate medical treatment with
beta-blockers and statins after acute myocardial infarction compared with Danish-
born residents? A register-based follow-up study.
Eur J Clin Pharmac
2010;
66
(7):
735–742. PubMed PMID: 20393695.
32. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J,
et al
. Patient, physician,
and payment predictors of statin adherence.
Med Care
2010;
48
(3): 196–202.
PubMed PMID: 19890219.
33. Traylor AH, Schmittdiel JA, Uratsu CS, Mangione CM, Subramanian U. Adherence
to cardiovascular disease medications: does patient-provider race/ethnicity
and language concordance matter?
J Gen Int Med
2010;
25
(11): 1172–1177.
PubMed PMID: 20571929. Pubmed Central PMCID: 2947630.
34. Sliwa K, Lyons JG, Carrington MJ, Lecour S, Marais AD, Raal FJ,
et al
. Different
lipid profiles according to ethnicity in the Heart of Soweto study cohort of de
novo presentations of heart disease.
Cardiovasc J Afr
2012;
23
(7): 389–395.
PubMed PMID: 22914997.
35. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential
for cholesterol management in patients with coronary heart disease in 15
European countries: findings from the EUROASPIRE II survey.
Atherosclerosis
2008;
197
(2): 710–717. PubMed PMID: 17765905. Epub 2007/09/04. eng.
36. Sudano I, Hess L, Noll G, Arnet D. Persistent dyslipidemia in statin-treated patients:
the focus on comprehensive lipid management survey in Swiss patients. Swiss
Med Weekly 2011; 141: w13200. PubMed PMID: 21574067. Epub 2011/05/17.
eng.
37. Eber B, Lautsch D, Fauer C, Drexel H, Pfeiffer KP, Traindl O,
et al
. Can LDL-
cholesterol targets be achieved in a population at high risk? Results of the non-
interventional study ACT II.
Curr Med Res Opin
2012;
28
(9): 1447–1454. PubMed
PMID: 22856551. Epub 2012/08/04. eng.
38. Bandgar TR, Faruqui AA. Managing dyslipidaemia: evolving role of combination
therapy.
J Indian Med Assoc
2011;
109
(8): 549–552. PubMed PMID: 22315861.
Epub 2012/02/10. eng.
39. Ito MK. Dyslipidemia: management using optimal lipid-lowering therapy.
Ann
Pharmacother
2012;
46
(10): 1368–1381. PubMed PMID: 23032652. Epub
2012/10/04. eng.
40. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid
lowering medication.
Cochrane Database Syst Rev
2010 (3): CD004371. PubMed
PMID: 20238331.
41. Dragomir A, Cote R, White M, Lalonde L, Blais L, Berard A,
et al
. Relationship
between adherence level to statins, clinical issues and health-care costs in real-life
clinical setting.
Value Health
2010;
13
(1): 87–94. PubMed PMID: 19695008.
42. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN,
et al
.
Medication nonadherence is associated with a broad range of adverse outcomes
in patients with coronary artery disease.
Am Heart J
2008;
155
(4): 772–779.
PubMed PMID: 18371492.
43. McGinnis BD, Olson KL, Delate TM, Stolcpart RS. Statin adherence and mortality
in patients enrolled in a secondary prevention program.
Am J Managed Care
2009;
15
(10): 689–695. PubMed PMID: 19845421.
44. Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients
with established cardiovascular disease: exploring healthy behaviour vs. drug
effects and 10-year follow-up of outcome.
Br J Clin Pharmacol
2008;
66
(1): 110–
116. PubMed PMID: 18492127. Pubmed Central PMCID: 2485263.
45. Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular
disease: a simulation study of the benefits of additional use of statins.
J Epidemiol
Commun Health
2010;
64
(2): 109–113. PubMed PMID: 20056964.
46. Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update.
Int
J Clin Pract
2012;
66
(3): 270–280. PubMed PMID: 22340447.